 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

It has been about a month since the last earnings report for Novavax (NVAX). Shares have lost about 3.2% in that time frame, underperforming the S&P 500.Will the recent negative trend continue...

Novavax (NVAX) Down 3.2% Since Last Earnings Report: Can It Rebound?

It has been about a month since the last earnings report for Myriad Genetics (MYGN). Shares have lost about 1% in that time frame, underperforming the S&P 500.Will the recent negative trend continue...

Why Is Myriad (MYGN) Down 1% Since Last Earnings Report?

SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and...

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

This price move could indicate a change in the trend, and may be a buy signal for investors...

Myriad Genetics (MYGN, $22.25) price moved above its 50-day Moving Average on March 20, 2024

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Myriad Genetics announces patent granted for SneakPeek Snap device

SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark...

Myriad Genetics Announces Patent Granted for SneakPeek  Snap Device

Sei Investments Co. lifted its position in Myriad Genetics, Inc. (NASDAQ:MYGN  Free Report) by 10.2% in the 3rd quarter, according to the company in its most recent filing with the Securities...

Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Purchased by Sei Investments Co.

Envestnet Asset Management Inc. lifted its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN  Free Report) by 80.7% during the 3rd quarter, according to the company in its most recent Form 13F...

Envestnet Asset Management Inc. Boosts Stake in Myriad Genetics, Inc. (NASDAQ:MYGN)

In a report released today, David Westenberg from Piper Sandler maintained a Hold rating on Myriad Genetics (MYGN Research Report), with a price...

Piper Sandler Sticks to Their Hold Rating for Myriad Genetics (MYGN)

Check out Ken Fisher Stock Picks &raquo;

 Download GuruFolio Report of Ken Fisher (Updated on 03/05/2024), Check out Larry Robbins Stock Picks &raquo;

 Download GuruFolio Report of Larry Robbins...

What's Driving Myriad Genetics Inc's Surprising 22% Stock Rally?

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Volume (M)	487,827.00
52-Wk High	$24.21
52-Wk Low	$13.82

MYGN Myriad Genetics, Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals